Company Filing History:
Years Active: 2020-2021
Title: Jens Petersen: Innovator in Pharmaceutical Chemistry
Introduction
Jens Petersen is a notable inventor based in Mölndal, Sweden. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that inhibit phosphatidylinositol 3-kinase (PI3K) activity. With a total of 2 patents, his work is recognized for its potential impact on treating various clinical conditions.
Latest Patents
Among his latest patents is the compound (S)-2-(1-cyclopropylethyl)-5-(4-methyl-2-((6-(2-oxopyrrolidin-1-yl)pyridin-2-yl)amino)thiazol-5-yl)-7-(methylsulfonyl)isoindolin-1-one. This compound serves as a phosphatidylinositol 3-kinase inhibitor, which is crucial for developing therapies aimed at inhibiting PI3K activity. Another significant patent involves novel compounds that inhibit phosphatidylinositol 3-kinase gamma (PI3Kδ) activity, which are useful in treating respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD).
Career Highlights
Jens Petersen is currently associated with AstraZeneca AB, a leading global biopharmaceutical company. His work at AstraZeneca focuses on innovative drug development, contributing to advancements in therapeutic options for various diseases.
Collaborations
Jens has collaborated with several talented individuals in his field, including Mickael Mogemark and Matthew Wd Perry. These collaborations have fostered a productive environment for innovation and research.
Conclusion
Jens Petersen's contributions to pharmaceutical chemistry and his innovative patents highlight his role as a key inventor in the industry. His work continues to pave the way for new treatments and therapies that can significantly improve patient outcomes.